With this extension, IXCHIQ ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU).

Valneva (VALN) announced that the European Commission has granted marketing authorization in Europe for Valneva’s single-dose vaccine, Ixchiq, for the prevention of disease caused by the ...

Ixchiq received marketing authorization in Europe for individuals 18 years and older in July 2024. The European Commission will now review the CHMP recommendation, and a decision on the label ...

Significant regulatory progress was made with IXCHIQ, including three additional approvals and ongoing label extension activities. The company expanded market access for IXCHIQ, launching in ...

This submission follows the recent positive opinion of the European Medicines Agency (EMA) on extension of Ixchiq label to adolescents in the European Union (EU). Ixchiq is the world’s first licensed ...